ATE452880T1 - 2-aminonicotinamid-derivate und ihre verwendung als vegf-rezeptor tyrosin-kinase inhibitoren - Google Patents

2-aminonicotinamid-derivate und ihre verwendung als vegf-rezeptor tyrosin-kinase inhibitoren

Info

Publication number
ATE452880T1
ATE452880T1 AT01946854T AT01946854T ATE452880T1 AT E452880 T1 ATE452880 T1 AT E452880T1 AT 01946854 T AT01946854 T AT 01946854T AT 01946854 T AT01946854 T AT 01946854T AT E452880 T1 ATE452880 T1 AT E452880T1
Authority
AT
Austria
Prior art keywords
group
mono
tyrosine kinase
receptor tyrosine
independently
Prior art date
Application number
AT01946854T
Other languages
English (en)
Inventor
Paul Manley
Guido Bold
Original Assignee
Novartis Ag
Novartis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag, Novartis Pharma Gmbh filed Critical Novartis Ag
Application granted granted Critical
Publication of ATE452880T1 publication Critical patent/ATE452880T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT01946854T 2000-01-27 2001-01-25 2-aminonicotinamid-derivate und ihre verwendung als vegf-rezeptor tyrosin-kinase inhibitoren ATE452880T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0001930.7A GB0001930D0 (en) 2000-01-27 2000-01-27 Organic compounds
PCT/EP2001/000835 WO2001055114A1 (en) 2000-01-27 2001-01-25 2-amino-nicotinamide derivatives and their use as vegf-receptor tyrosine kinase inhibitors

Publications (1)

Publication Number Publication Date
ATE452880T1 true ATE452880T1 (de) 2010-01-15

Family

ID=9884488

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01946854T ATE452880T1 (de) 2000-01-27 2001-01-25 2-aminonicotinamid-derivate und ihre verwendung als vegf-rezeptor tyrosin-kinase inhibitoren

Country Status (24)

Country Link
US (1) US6624174B2 (de)
EP (2) EP1259487B8 (de)
JP (1) JP3894793B2 (de)
KR (1) KR100554988B1 (de)
CN (1) CN1216867C (de)
AT (1) ATE452880T1 (de)
AU (1) AU771626B2 (de)
BR (1) BR0107805A (de)
CA (1) CA2396590C (de)
CZ (1) CZ20022582A3 (de)
DE (1) DE60140860D1 (de)
ES (2) ES2490191T3 (de)
GB (1) GB0001930D0 (de)
HU (1) HUP0204083A3 (de)
IL (2) IL150481A0 (de)
MX (1) MXPA02007319A (de)
NO (1) NO323826B1 (de)
NZ (1) NZ520005A (de)
PL (1) PL356307A1 (de)
PT (2) PT1259487E (de)
RU (1) RU2296124C2 (de)
SK (1) SK287426B6 (de)
WO (1) WO2001055114A1 (de)
ZA (1) ZA200205988B (de)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090098065A1 (en) * 2000-01-11 2009-04-16 Avikam Harel Composition and methods for the treatment of skin disorders
US7419428B2 (en) * 2000-04-28 2008-09-02 Igt Cashless transaction clearinghouse
DE10023492A1 (de) * 2000-05-09 2001-11-22 Schering Ag Aza- und Polyazanthranylamide und deren Verwendung als Arzneimittel
JP4341949B2 (ja) 2000-09-01 2009-10-14 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド アザ複素環式誘導体およびその治療的使用
JP4361727B2 (ja) 2000-09-11 2009-11-11 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド チロシンキナーゼインヒビターとしてのキノリノン誘導体
US7102009B2 (en) 2001-01-12 2006-09-05 Amgen Inc. Substituted amine derivatives and methods of use
US20020147198A1 (en) * 2001-01-12 2002-10-10 Guoqing Chen Substituted arylamine derivatives and methods of use
US7105682B2 (en) 2001-01-12 2006-09-12 Amgen Inc. Substituted amine derivatives and methods of use
US6995162B2 (en) * 2001-01-12 2006-02-07 Amgen Inc. Substituted alkylamine derivatives and methods of use
US6878714B2 (en) 2001-01-12 2005-04-12 Amgen Inc. Substituted alkylamine derivatives and methods of use
US20030134836A1 (en) * 2001-01-12 2003-07-17 Amgen Inc. Substituted arylamine derivatives and methods of use
IL158783A0 (en) * 2001-05-08 2004-05-12 Schering Ag Selective anthranilamide pyridine amides as inhibitors of vegfr-2 and vegfr-3
TWI315982B (en) 2001-07-19 2009-10-21 Novartis Ag Combinations comprising epothilones and pharmaceutical uses thereof
US20030195192A1 (en) * 2002-04-05 2003-10-16 Fortuna Haviv Nicotinamides having antiangiogenic activity
GB0206215D0 (en) 2002-03-15 2002-05-01 Novartis Ag Organic compounds
US7307088B2 (en) 2002-07-09 2007-12-11 Amgen Inc. Substituted anthranilic amide derivatives and methods of use
US7615565B2 (en) 2002-07-31 2009-11-10 Bayer Schering Pharma Aktiengesellschaft VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridines
CA2493026C (en) * 2002-07-31 2011-05-24 Bayer Schering Pharma Aktiengesellschaft Vegfr-2 and vegfr-3 inhibitory anthranilamide pyridines
CA2496164C (en) 2002-08-23 2010-11-09 Chiron Corporation Benzimidazole quinolinones and uses thereof
US20040067985A1 (en) * 2002-10-04 2004-04-08 Fortuna Haviv Method of inhibiting angiogenesis
GB0229022D0 (en) * 2002-12-12 2003-01-15 Novartis Ag Organic Compounds
WO2004078723A1 (ja) 2003-03-07 2004-09-16 Santen Pharmaceutical Co. Ltd. ４－ピリジルアルキルチオ基を置換基として有する新規化合物
US7129252B2 (en) * 2003-06-16 2006-10-31 Guoqing P Chen Six membered amino-amide derivatives an angiogenisis inhibitors
US20080085902A1 (en) * 2003-09-23 2008-04-10 Guido Bold Combination Of A Vegf Receptor Inhibitor Or With A Chemotherapeutic Agent
CA2539230A1 (en) * 2003-09-23 2005-03-31 Novartis Ag Combinations of a vegf receptor inhibitor with other therapeutic agents
US7592466B2 (en) 2003-10-09 2009-09-22 Abbott Laboratories Ureas having antiangiogenic activity
TWI347940B (en) 2003-11-07 2011-09-01 Novartis Ag Methods for synthesizing quinolinone compounds
UA89035C2 (ru) 2003-12-03 2009-12-25 Лео Фарма А/С Эфиры гидроксамовых кислот и их фармацевтическое применение
ATE512950T1 (de) 2004-02-17 2011-07-15 Santen Pharmaceutical Co Ltd Neue cyclische verbindung mit 4- pyridylalkylthiogruppe mit darin eingeführtem (un)substituiertem amino
DE102004009238A1 (de) * 2004-02-26 2005-09-08 Merck Patent Gmbh Arylamid-Derivate
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
US7507748B2 (en) 2004-07-22 2009-03-24 Amgen Inc. Substituted aryl-amine derivatives and methods of use
EP1655295A1 (de) 2004-11-03 2006-05-10 Schering Aktiengesellschaft Anthranilamid-Pyridinharnstoffe als VEGF Rezeptor Kinase Inhibitoren
US7906533B2 (en) 2004-11-03 2011-03-15 Bayer Schering Pharma Ag Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors
EP1657241A1 (de) 2004-11-03 2006-05-17 Schering Aktiengesellschaft Neue Antranilamidpyrdinharnstoffe mit hemmender Wirkung auf VEGF-Rezeptor Kinase
WO2006070878A1 (ja) * 2004-12-28 2006-07-06 Astellas Pharma Inc. カルボン酸誘導体またはその塩
EP2410043A3 (de) 2004-12-29 2013-01-23 Hadasit Medical Research Services And Development Ltd. Stammzellenkultursysteme
US8597947B2 (en) 2004-12-29 2013-12-03 Hadasit Medical Research Services & Development Limited Undifferentiated stem cell culture systems
ES2351613T3 (es) * 2005-03-03 2011-02-08 Santen Pharmaceutical Co., Ltd. Nuevo compuesto cíclico que tiene un grupo quinolilalquiltio.
ES2548729T3 (es) 2005-03-31 2015-10-20 Santen Pharmaceutical Co., Ltd. Nuevo compuesto cíclico que tiene grupo pirimidinilalquiltio
AU2006247062A1 (en) 2005-05-17 2006-11-23 Novartis Ag Methods for synthesizing heterocyclic compounds
US8247556B2 (en) 2005-10-21 2012-08-21 Amgen Inc. Method for preparing 6-substituted-7-aza-indoles
BRPI0619370A2 (pt) 2005-11-29 2011-09-27 Novartis Ag formulações de quinolinonas
AR059066A1 (es) * 2006-01-27 2008-03-12 Amgen Inc Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf)
GB0612721D0 (en) 2006-06-27 2006-08-09 Novartis Ag Organic compounds
JP5216341B2 (ja) 2007-01-29 2013-06-19 参天製薬株式会社 血管新生阻害活性を有する新規オキサジアゾール誘導体およびチアジアゾール誘導体
US8956866B2 (en) 2007-04-18 2015-02-17 Hadasit Medical Research Services And Development Ltd. Retinal pigment epithelial cells differentiated from embryonic stem cells with nicotinamide and activin A
EP2238448B1 (de) * 2008-01-07 2016-04-06 Ortho-Clinical Diagnostics, Inc. Kalibrator/steuerung für simultanen test von untereinander komplexierungsfähigen proteinen
EP2474323A3 (de) * 2008-03-26 2012-10-10 Novartis AG Imidazoquinolin- und Pyrimidinderivate als starke Modulatoren von VEGF-gesteuerten angiogenetischen Prozessen
US8350026B2 (en) 2008-08-27 2013-01-08 Leo Pharma A/S VEGF-2 receptor and protein tyrosine kinase inhibitors and pharmaceutical use thereof
CN101676267B (zh) * 2008-09-16 2012-12-26 江苏恒瑞医药股份有限公司 N-[4-(1-氰基环戊基)苯基]-2-(4-吡啶甲基)氨基-3-吡啶甲酰胺的盐
AU2010294209A1 (en) 2009-09-10 2012-03-29 Irm Llc Ether derivatives of bicyclic heteroaryls
AU2010303567B2 (en) * 2009-10-06 2016-06-09 Millennium Pharmaceuticals, Inc Heterocyclic compounds useful as PDK1 inhibitors
WO2011064211A1 (en) 2009-11-25 2011-06-03 Novartis Ag Benzene-fused 6-membered oxygen-containing heterocyclic derivatives of bicyclic heteroaryls
CN102947274A (zh) 2010-06-17 2013-02-27 诺瓦提斯公司 联苯基取代的1,3-二氢-苯并咪唑-2-亚基胺衍生物
EP2582681A1 (de) 2010-06-17 2013-04-24 Novartis AG Piperidinylsubstituierte 1,3-dihydro-benzoimidazol-2-ylidenaminderivate
CN103492390A (zh) 2011-03-08 2014-01-01 诺瓦提斯公司 氟苯基双环杂芳基化合物
KR101412794B1 (ko) * 2011-07-27 2014-07-01 보령제약 주식회사 혈관생성억제 작용을 갖는 신규한 화합물, 이의 제조방법 및 이를 포함하는 약학적 조성물
AU2013259565A1 (en) * 2012-05-08 2014-11-13 Anvyl Llc Alpha 7 nicotinic acetylcholine receptor allosteric modulators, their derivatives and uses thereof
RU2718054C2 (ru) 2013-11-28 2020-03-30 СиЭсЭл ЛИМИТЕД Способ лечения нефропатии
CA2940237C (en) 2014-02-21 2023-03-07 Frost Biologic, Inc. Antimitotic amides for the treatment of cancer and proliferative disorders
IL305070B2 (en) 2014-12-30 2025-11-01 Cell Cure Neurosciences Ltd Rpe cell populations and methods of generating same
JP2018502575A (ja) 2014-12-30 2018-02-01 セル キュア ニューロサイエンシズ リミテッド 網膜色素上皮細胞集団の評価法
JP7055095B2 (ja) 2015-07-29 2022-04-15 ハダシット メディカル リサーチ サービシーズ アンド ディベロップメント リミテッド 網膜色素上皮細胞の大規模生産
US11090337B2 (en) 2015-08-05 2021-08-17 Cell Cure Neurosciences Ltd Preparation of photoreceptors for the treatment of retinal diseases
DK3331994T3 (da) 2015-08-05 2022-11-21 Cell Cure Neurosciences Ltd Fremstilling af retinale pigmentepitelceller
BR112018004065B1 (pt) 2015-08-31 2023-12-12 Dong-A Socio Holdings Co., Ltd Compostos heterocíclicos, composições farmacêuticas compreendendo os ditos compostos e usos terapêuticos dos mesmos
HRP20250311T1 (hr) 2015-10-26 2025-07-18 Cell Cure Neurosciences Ltd. Priprema stanica pigmentnog epitela mrežnice
CA3052872A1 (en) 2017-02-08 2018-08-16 Hadasit Medical Research Services And Development Ltd. Photoreceptor cells for the treatment of retinal diseases
CA3056653A1 (en) 2017-03-16 2018-09-20 Lineage Cell Therapeutics, Inc. Methods for the treatment of retinal diseases
CA3079076A1 (en) 2017-10-18 2019-04-25 Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus Methods and compounds for improved immune cell therapy
AU2017444054B2 (en) 2017-12-21 2021-10-07 Hefei Institutes Of Physical Science, Chinese Academy Of Sciences Class of pyrimidine derivative kinase inhibitors
CN111741735A (zh) 2017-12-29 2020-10-02 细胞治疗神经科学有限公司 视网膜色素上皮细胞组合物
CN113038951B (zh) 2018-09-20 2024-04-30 耶达研究及发展有限公司 治疗肌萎缩侧索硬化的方法
EP3754014A1 (de) 2019-06-21 2020-12-23 Centre d'Etude des Cellules Souches (CECS) Automatisiertes verfahren zur herstellung von retinalen pigmentepithelzellen
US20220395553A1 (en) 2019-11-14 2022-12-15 Cohbar, Inc. Cxcr4 antagonist peptides
TWI853255B (zh) 2021-06-09 2024-08-21 美商譜系細胞治療公司 治療視網膜疾病及病況之方法及組成物
MX2024001213A (es) 2021-07-28 2024-03-14 Lineage Cell Therapeutics Inc Expansion de celulas del epitelio pigmentario retiniano.
IL316305A (en) 2022-04-25 2024-12-01 Hadasit Med Res Service Methods and preparations for treating vision loss

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2058656T3 (es) * 1989-04-20 1994-11-01 Boehringer Ingelheim Pharma 5,11-dihidro-6h-dipirido(3,2-b:2',3'-e)(1,4)diazepin-6-onas y su uso en la prevencion o tratamiento del sida.
US5728708A (en) * 1993-10-01 1998-03-17 Novartis Corporation Pharmacologically active pyridine derivatives and processes for the preparation thereof
AU720429B2 (en) 1996-08-23 2000-06-01 Novartis Ag Substituted pyrrolopyrimidines and processes for their preparation
SK132899A3 (en) 1997-04-04 2000-09-12 Pfizer Prod Inc NICOTINAMIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONì (54) COMPRISING THEM
AU8033598A (en) 1997-06-18 1999-01-04 Nissan Chemical Industries Ltd. Pyridine compounds and herbicides
AR013693A1 (es) 1997-10-23 2001-01-10 Uriach & Cia Sa J Nuevas piperidinas y piperazinas como inhibidores de la agregacion plaquetaria
CA2332957A1 (en) * 1998-06-05 1999-12-09 Boehringer Ingelheim Pharmaceuticals, Inc. Substituted 1-(4-aminophenyl)pyrazoles and their use as anti-inflammatory agents
CA2358091A1 (en) 1998-12-23 2000-07-06 Eli Lilly And Company Antithrombotic amides
NZ513639A (en) * 1999-04-15 2004-02-27 Bristol Myers Squibb Co Cyclic protein tyrosine kinase inhibitors
AU2001231143A1 (en) 2000-01-27 2001-08-07 Cytovia, Inc. Substituted nicotinamides and analogs as activators of caspases and inducers of apoptosis and the use thereof

Also Published As

Publication number Publication date
US20030032656A1 (en) 2003-02-13
JP2003520853A (ja) 2003-07-08
DE60140860D1 (de) 2010-02-04
US6624174B2 (en) 2003-09-23
EP2168948B1 (de) 2014-05-07
HK1050895A1 (en) 2003-07-11
SK287426B6 (sk) 2010-09-07
KR100554988B1 (ko) 2006-02-24
NZ520005A (en) 2004-02-27
BR0107805A (pt) 2002-10-22
AU2849901A (en) 2001-08-07
NO20023218L (no) 2002-09-16
CA2396590A1 (en) 2001-08-02
WO2001055114A1 (en) 2001-08-02
IL150481A (en) 2009-09-22
MXPA02007319A (es) 2002-11-29
EP1259487B8 (de) 2014-04-23
ES2490191T3 (es) 2014-09-03
CZ20022582A3 (cs) 2002-10-16
JP3894793B2 (ja) 2007-03-22
AU771626B2 (en) 2004-04-01
RU2296124C2 (ru) 2007-03-27
SK10852002A3 (sk) 2003-05-02
CN1216867C (zh) 2005-08-31
HUP0204083A2 (hu) 2003-03-28
PT1259487E (pt) 2010-03-26
NO20023218D0 (no) 2002-07-02
IL150481A0 (en) 2002-12-01
CA2396590C (en) 2011-03-01
KR20020071973A (ko) 2002-09-13
ES2338407T3 (es) 2010-05-07
NO323826B1 (no) 2007-07-09
HUP0204083A3 (en) 2005-03-29
PL356307A1 (en) 2004-06-28
CN1396912A (zh) 2003-02-12
EP1259487A1 (de) 2002-11-27
GB0001930D0 (en) 2000-03-22
EP1259487B1 (de) 2009-12-23
PT2168948E (pt) 2014-08-26
EP2168948A1 (de) 2010-03-31
ZA200205988B (en) 2003-07-28

Similar Documents

Publication Publication Date Title
DE60140860D1 (de) 2-aminonicotinamid-derivate und ihre verwendung als vegf-rezeptor tyrosin-kinase inhibitoren
DE69418704D1 (de) Anthranilsäure derivate
MX2007006821A (es) Derivados de 2,4 (4,6) pirimidina.
ATE206412T1 (de) Heterocyclische verbindungen als bradykinin antagonisten
DK0873319T3 (da) Quinazolinderivater
DE60140456D1 (de) Aza heterocyclische derivate und ihre therapeutische verwendung
ATE496035T1 (de) Stickstoffenthaltende heterocyclische verbindungen
ATE274512T1 (de) Phenylharnstoffe und phenylthioharnstoffe als orexinrezeptorantagonisten
EA200601235A1 (ru) Производные тиазола
EP1396493A4 (de) Heterocyclische verbindungen
ATE311358T1 (de) Immunoregulierende verbindungen, deren derivate und ihre verwendung
DE3781080D1 (de) 2-substituierte-e-kondensierte(1,2,4)triazolo-(1,5-c)pyrimidine, pharmazeutische zubereitungen und ihre verwendung.
NO900542D0 (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive benzokondenserte n-holdige heterocykliske derivater.
ATE324890T1 (de) Zusammensetzung enthaltend einen angiotensin-ii- rezeptor-antagonist und einen diuretikum und deren verwendung zur behandlung von bluthochdruck
DE69225240D1 (de) Substituierte imidazol derivate und deren herstellung und verwendung
TR200103789T2 (tr) Tirozin kinaz inhibitörleri olarak ikameli 1,4-dihidroindeno[1,2-C]pirazoller.
PT1315730E (pt) Derivados de 1-[alquil],1-[(heteroaril)-alquil] e 1-[(aril)-alquil]-7-piridinil-imidazo[1,2-a]pirimidin-5(1h)-ona
DK0780125T3 (da) Anvendelse af hydantoinderivater til fremstilling af et lægemiddel til behandling af sygdomme associeret med tilstedeværelse af aktivt oxygen og frie radikaler
MXPA02011464A (es) Derivados 1,4-diazepan-2,5-diona y su uso como antagonistas del receptor de la nk-1.
DE69720966D1 (de) Benzo[c]chinolizin derivate,deren herstellung und verwendung als 5-alfa-reduktase inhibitoren
BR0209332A (pt) Derivados de ftalazina com atividade inibidora da angiogênese
DE502004007387D1 (de) Triazolverbindungen und ihre therapeutische verwendung
AR021094A1 (es) Compuestos heterociclicos inhibidores de la fosfodiesterasa iv y su uso para el tratamiento de enfermedades inflamatorias
NO20022456L (no) Pyrazolo[1,5-d][1,2,4]triazinerderivater for forbedring av kognisjon
EA199800720A1 (ru) Гетероциклические производные эрголина в качестве лигандов 5-htia рецептора

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1259487

Country of ref document: EP